Partnership projects


15 million people suffer from a stroke every year. However, because of selection criteria, the only available treatment, acute thrombolytic therapy (pharmacological or mechanical), is administered to less than 10% of all patients. The PB008 (MAGBBRIS) project aims to demonstrate use of nanotechnology to enable delivery of therapeutic growth factors to damaged brain cells, and ultimately, to ameliorate clinical outcomes.


The project’s objective is to demonstrate that growth factors, which are secreted by endothelial progenitor cells and with proven potential for tissue repair, can be encapsulated in magnetic biomaterials and delivered into mouse brains to induce tissue repair, which might present a viable treatment option for stroke patients.


According to WHO statistics, stroke affects 15 million people worldwide each year. Unfortunately, whereas 5 million of these people will die, another 5 million will survive with neurological deficits limiting their functional independence. Available treatments for stroke include thrombolytics such as tissue plasminogen activator, used to dissolve a clot in the brain, or endovascular treatment, used for retrieval or mechanical disruption of a clot.

The PB008 project aims to demonstrate that growth factors, secreted by endothelial progenitor cells, can be encapsulated in magnetic biomaterials and safely transplanted into mouse brains, where they can successfully induce tissue repair. Applied biomaterials will be validated for their potential cytotoxicity and therapeutic properties, both in vitro and in vivo; imaging techniques (PET, MRI and optical imaging) will be used to monitor delivery of the biomaterials and to assess for therapeutic effects over time, using an in vivo mouse model of cerebral ischemia. We will also investigate  feasibility of secreted growth factor productions in accordance to GMP standards. Results of the PB008 project are expected to serve as a foundation for a therapy that could be translated to a clinical stage as a non-invasive, safe, and widely available therapeutic option for stroke patients.


Pure Biologics’ role in the MAGBBRIS project is to develop and produce under GMP-like conditions, high quality and validated cell secretomes, containing the growth factors to be used in preclinical animal studies.


Pure Biologics has finished the production of the final three validation rounds of secretome under GMP-like conditions. The obtained biomaterial has been verified by qualitative, quantitative, and functional tests ensuring constant control of production batches. The preparation of GMP-compliant documentation of the production process and quality assessment of the biomaterial has also been completed.


Title: “New MAGnetic Biomaterials for Brain Repair and Imaging after Stroke” (MAGBBRIS)
Program: Measure „EuroNanoMed III Joint Transnational Call for Proposals (2017) for European Innovative and Research & Technological Development Projects in Nanomedicine
Value: PLN 1 148 864,50 (the entire consortium: PLN 6 430 953,54)
Contribution of European Funds: PLN 804 205,15 (the entire consortium: PLN 4 225 283,50)
Start: 1st January 2018
End: 30th April 2021
Consortium members: Fundació Hospital Universitari Vall d’ Hebron – Institut de Recerca (Spain), Agencia Estatal Consejo Superior de Investigaciones Científicas (Spain), University of Artois, Faculty Jean Perrin (France), Ospedale San Raffaele IRCCS (Italy), Institute of experimental physics, Slovak Academy of Sciences (Slovakia) and Pure Biologics S.A.

Menu Close

We use cookies to give you the best browsing experience, site traffic analysis, and advertisement management.

Pure Biologics - Harnessing the power of antibodies and aptamers